This is expected to boost the company’s Life Sciences segment.
The new BD PurPrep formulation comprises of a fluid-resistant, film-forming polymer designed to facilitate drape adhesion and help create a durable anti-microbial barrier that helps iodine bind to the skin for residual antimicrobial activity. In an irrigation study emulating real-world clinical practice, BD PurPrep patient preoperative skin preparation with sterile solution stayed on the skin immediately following a saline challenge.
Other than BD ChloraPrep patient preoperative skin preparation, BD PurPrep is the first and only fully sterile skin preparation available that utilizes a single-use applicator specifically designed to curb cross-contamination and promote aseptic non-touch technique. The BD PurPrep patient preoperative skin preparation is an effective skin preparation option when the use of a chlorhexidine gluconate is contra-indicated or the patient is sensitive to CHG.
By developing fully sterile PurPrep and ChloraPrep, BD is offering healthcare experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
By adding a non-CHG, fully sterile skin preparation option, BD is broadening the availability of tools to help mitigate the risk of infection in patients with CHG sensitivities and during procedures where CHG/IPA is not indicated.
Notably, the new BD PurPrep sterile solution will include a mark to indicate that the solution is sterile. Though not required by the FDA, BD developed this mark to differentiate sterile solutions from non-sterile antiseptic skin preparations. Also, BD PurPrep will replace Prevail and Prevail FX, and is available now through BD and other distribution partners.
In February 2020, the company announced that BD Synapsys microbiology informatics solution, the company’s integrated diagnostics informatics platform, has been authorized by the Underwriters Laboratory Cybersecurity Assurance Program. This independent program utilizes standardized, testable criteria for evaluating software vulnerabilities and weaknesses.
Around the same time, the company announced that the BD Kiestra ReadA is device listed with the FDA. The BD Kiestra ReadA, which is available as a standalone instrument, helps enhance operational efficiency in clinical microbiology laboratories by automating routine plate-management tasks and offering proficiency through standardized digital image acquisition.
Per a report by Grand View Research, the global infection control market size was estimated at $150.4 billion in 2016 and is anticipated to grow at a CAGR of 6.2% throughout the forecast period of 2018-2025. Hence, this launch is well-timed.
Over the past year, the stock has lost 0.1% compared with the 11.8% decline of its industry.
BD currently has a Zacks Rank#3 (Hold).
A few better-ranked stocks from the broader medical space include Laboratory Corporation of America Holdings LH, Surmodics SRDX and Quest Diagnostics DGX.
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy).
Quest Diagnostics’ long-term earnings growth rate is estimated at 7.6%. It currently carries a Zacks Rank #1.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.